Key Takeaways
- ARK Invest liquidated 3,578 Meta shares valued at approximately $2.1 million from three separate funds
- The firm offloaded 95,090 Roku shares representing roughly $9.1 million across various ETFs
- ARK acquired 84,939 Tempus AI shares for approximately $4.1 million during Wednesday’s session
- Tempus AI has climbed to become the third-largest position in ARK Innovation ETF, accounting for around 5% of total assets
- Meta faced a social media addiction lawsuit verdict and announced workforce reductions affecting hundreds of employees
Cathie Wood’s investment firm ARK Invest executed strategic portfolio adjustments on Wednesday, March 25, divesting from Meta and Roku while channeling resources toward healthcare artificial intelligence specialist Tempus AI.
The firm disposed of 3,578 Meta shares distributed among three funds. Calculated at the closing market price, the transaction generated approximately $2.1 million. Following this adjustment, ARK Innovation ETF maintains ownership of roughly 105,000 Meta shares, representing a value near $63 million and constituting about 1% of fund assets.
Meta experienced a particularly eventful trading session. A jury delivered a verdict finding both the company and Google’s YouTube negligent for developing products that caused harm to young users in a precedent-setting social media addiction case. Both technology giants announced intentions to challenge the ruling.
Meta simultaneously introduced an ambitious executive compensation structure targeting a 500% stock appreciation and $9 trillion market capitalization by 2031. The corporation confirmed to Barron’s that workforce reductions would affect several hundred positions spanning sales, recruitment, and virtual reality departments. Meta’s stock closed the session with a modest 0.3% gain despite these developments.
ARK simultaneously divested 95,090 Roku shares across ARKK, ARKW, and ARKF funds, generating approximately $9.1 million. This transaction follows a substantial Roku divestment executed one day earlier on March 24.
Additional portfolio reductions included 30,174 Teradyne shares valued at roughly $9.7 million, along with 205,019 Bullish shares across three ETFs totaling about $7.7 million. ARK has maintained steady Bullish share sales throughout the preceding week.
Further divestments encompassed 62,393 Kratos Defense shares and 27,647 Natera shares, worth $4.8 million and $5.4 million respectively.
Tempus AI Emerges as ARK’s Strategic Priority
Regarding acquisitions, ARK’s primary transaction involved Tempus AI. The investment firm purchased 84,939 shares through ARKK and ARKG ETFs, deploying approximately $4.1 million.
Tempus AI declined 4.2% during Wednesday’s session and has experienced a 21% decrease year-to-date in 2026. ARK’s acquisition appears timed to capitalize on the price decline.
ARK Innovation ETF currently maintains approximately 6.3 million Tempus AI shares valued above $294 million. This position ranks as the fund’s third-largest holding, trailing only Tesla and Crispr Therapeutics, representing roughly 5% of total portfolio value.
Strategic Portfolio Transformation Continues
Wednesday’s transactions reflect a consistent reallocation strategy. The investment firm has systematically reduced exposure to Roku, Teradyne, and Bullish through multiple consecutive trading sessions.
Concurrently, ARK has steadily expanded its Tempus AI holdings. Tempus AI operates as a healthcare technology enterprise leveraging artificial intelligence for medical data analysis and oncology treatment optimization.
Smaller acquisitions during the session included positions in Archer Aviation, Beam Therapeutics, and additional companies.
The ARK Innovation ETF concluded Wednesday’s trading with a 1.3% advance.
